Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.32 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233448 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2TP53TSHRALDH1A1LMNA | |
| SCHEMBL1233974 | 0.78 | KDM4E (0.33) | TP53SAE1UBA2GCGRALDH1A1 | |
| SCHEMBL1234069 | 0.78 | GCGR (0.34) | SAE1UBA2GCGRALDH1A1LMNA | |
| SCHEMBL1232513 | 0.77 | GRK6 (0.34) | SAE1UBA2GCGRALDH1A1POLB | |
| SCHEMBL1234246 | 0.77 | GCGR (0.38) | SAE1UBA2GCGRALDH1A1POLB | |
| SCHEMBL1232442 | 0.71 | TP53 (0.36) | SMN1; SMN2TP53TSHRALDH1A1LMNA | |
| SCHEMBL1231871 | 0.70 | TLR7 (0.47) | SAE1UBA2TLR8 | |
| SCHEMBL1234329 | 0.65 | SMPD1 (0.38) | SMN1; SMN2ALDH1A1HDAC1HDAC8 | |
| SCHEMBL1232628 | 0.65 | PTGER1 (0.45) | HDAC1HDAC8 | |
| SCHEMBL1233653 | 0.65 | TSHR (0.36) | TP53SAE1UBA2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9145410-B2 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2012-05-17 | — | — | US | disclosed |
| US-7879849-B2 | such as 1-(2-Methylpropyl)-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine, used as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-7544697-B2 | Pyrazolopyridines and analogs thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1696912-A4 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | SMN1; SMN2 3916/4885TP53 35/4885SAE1 3581/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | SMN1; SMN2 4015/4885TP53 46/4885SAE1 3486/4885 |
| US-20120121651-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL4I1, IL2 | SMN1; SMN2 3916/4885TP53 35/4885SAE1 3581/4885 |
| US-20090318435-A1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | IL4, IL2, IL4I1 | SMN1; SMN2 4015/4885TP53 46/4885SAE1 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.